Comprehensive analysis of DTYMK in pan-cancer and verification in lung adenocarcinoma.
Comprehensive analysis of DTYMK in pan-cancer and verification in lung adenocarcinoma.
复制标题
DOI：
10.1042/bsr20221170
复制
发表时间：
2022-10-28
影响因子：
4
通讯作者：
中科院分区：
文献类型：
--
作者：
先前的文献报道脱氧胸苷酸激酶（DTYMK）基因参与癌症的进展。然而，其在泛癌分析中的意义和具体分子机制仍知之甚少。在本研究中，我们对 DTYMK 基因及其在广谱人类肿瘤中的临床相关性进行了全面研究。此外，还探讨了 DTYMK 基因与肿瘤免疫原性特征之间的关联。考虑到泛癌分析的结果，选择特定的肿瘤肺腺癌（LUAD）来进一步研究DTYMK诱导的信号通路和肿瘤进展中的细胞间通讯。我们的研究结果表明，DTYMK 可能成为各种癌症的预后和免疫治疗的新生物标志物。重要的是，DTYMK有望成为LUAD临床预后和肿瘤个性化治疗的指导标记基因。
Previous documents have reported that the deoxythymidylate kinase (DTYMK) genes were involved in the progression of cancers. However, its significance in the analysis of pan-cancer and specific molecular mechanism were still poorly understood. In the present study, we conducted a comprehensive study of the DTYMK gene associated with its clinical relevance across a broad-spectrum of human tumors. In addition, association among DTYMK gene and tumor immunogenic features was also explored. Considering the results of pan-cancer analysis, the specific tumor lung adenocarcinoma (LUAD) was chosen to further study the DTYMK-induced signaling pathways and intercellular communications in tumor progression. Our findings demonstrated that DTYMK may be a new biomarker for the prognosis and immunotherapy in various cancers. Importantly, DTYMK was expected to be a guiding marker gene for clinical prognosis and tumor personalized therapy in LUAD.